HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

ChimeriVax

a vaccine against the West Nile virus; uses yellow fever 17D as a live vector for envelope genes of West Nile & other flaviviruses
Networked: 41 relevant articles (3 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Guirakhoo, Farshad: 14 articles (07/2010 - 01/2002)
2. Monath, Thomas P: 12 articles (09/2007 - 01/2002)
3. Lang, Jean: 6 articles (01/2014 - 01/2005)
4. Catalan, John: 5 articles (01/2018 - 02/2002)
5. Pugachev, Konstantin V: 5 articles (01/2018 - 10/2005)
6. Guirakhoo, F: 5 articles (05/2004 - 02/2000)
7. Monath, T P: 5 articles (09/2003 - 02/2000)
8. Guy, Bruno: 4 articles (01/2014 - 01/2007)
9. Brown, Nathan: 4 articles (01/2010 - 01/2005)
10. Arroyo, J: 4 articles (09/2003 - 02/2000)

Related Diseases

1. Yellow Fever
2. Japanese Encephalitis
3. Infections
09/01/2003 - "'ChimeriVax-West Nile(vet)' is being developed for use as a veterinary vaccine to protect against WN infection. "
03/01/2008 - "In light of the low-level viremias that have been observed after vaccination in human volunteers coupled with low mosquito infectivity, it is predicted that the risk of mosquito infection and transmission of ChimeriVax vaccine recombinant/revertant viruses in nature is minimal."
10/01/2006 - "Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE)."
03/01/2009 - "We show that (i) a three-dose vaccination schedule with JE-VAX provides cross-protective immunity, albeit only partial in the more severe challenge model; (ii) a single dose of ChimeriVax-JE gives complete protection in both challenge models; (iii) the cross-protective immunity elicited with ChimeriVax-JE is durable (>or=5 months) and broad (also giving protection against West Nile virus); (iv) humoral and cellular immunities elicited with ChimeriVax-JE contribute to protection against lethal challenge with MVEV; (v) ChimeriVax-JE remains fully attenuated in immunodeficient mice lacking type I and type II interferon responses; and (vi) immunization with JE-VAX, but not ChimeriVax-JE, can prime heterologous infection enhancement in recipients of vaccination on a low-dose schedule, designed to mimic vaccine failure or waning of vaccine-induced immunity. "
03/01/2008 - "Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes."
4. Dengue (Dengue Fever)
5. Viremia

Related Drugs and Biologics

1. Vaccines
2. Attenuated Vaccines
3. Interferon-gamma (Interferon, gamma)
4. Antigens
5. Protein Subunit Vaccines
6. DNA Vaccines
7. Viral Vaccines
8. Complementary DNA (cDNA)
9. Proteins (Proteins, Gene)
10. Neutralizing Antibodies

Related Therapies and Procedures

1. Stents
2. Drug-Eluting Stents
3. Therapeutics
4. Intramuscular Injections
5. Injections